id: NEW:clinician_aud_pharmacotherapy_reluctance_to_sud_medication_treatment_rate_oud
name: Clinician Reluctance to Prescribe AUD Medications â†’ SUD Medication Treatment Rate
from_node:
  node_id: NEW:clinician_aud_pharmacotherapy_reluctance
  node_name: Clinician Reluctance to Prescribe AUD Medications
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: SUD Medication Treatment Rate
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Clinicians lack confidence or training in prescribing AUD pharmacotherapy despite evidence
  of efficacy'
- 'Step 2: Reluctance to prescribe leads to underutilization of available FDA-approved and off-label medications'
- 'Step 3: Patients with AUD receive psychosocial intervention alone, which has higher relapse rates'
- 'Step 4: Population-level medication treatment rates for substance use disorders remain low'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: Youngjung Kim et al. 2018. "Practical outpatient pharmacotherapy for alcohol use disorder."
    https://doi.org/10.7573/dic.212308
  supporting_citations:
  - 'Mark TL et al. (2009). Alcohol and opioid dependence medications: Prescription trends, overall and
    by physician specialty. Drug and Alcohol Dependence.'
  - Harris AH et al. (2012). Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
  - 'Thomas CP et al. (2014). Medication-assisted treatment with buprenorphine: Assessing the evidence.'
  doi: 10.7573/dic.212308
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Clinician reluctance to prescribe AUD medications represents a critical healthcare system
  barrier. Despite medications being efficacious, safe, and cost-effective, provider-level hesitancy creates
  a treatment gap that disproportionately affects AUD patients who could benefit from pharmacological
  support.
spatial_variation:
  varies_by_geography: true
  variation_notes: Prescribing patterns likely vary by healthcare setting, specialty, and region, though
    not explicitly quantified
moderators:
- name: clinical_guidelines_availability
  direction: weakens
  strength: moderate
  description: Access to current treatment guidelines and practical prescribing strategies may reduce
    clinician reluctance
- name: outpatient_vs_inpatient_setting
  direction: strengthens
  strength: moderate
  description: Outpatient settings may have less infrastructure for managing AUD pharmacotherapy, increasing
    reluctance
structural_competency:
  equity_implications: This mechanism identifies the structural barrier as residing in the healthcare
    delivery system and medical education, not in patient characteristics. The reluctance is framed as
    a clinician/system issue that requires intervention through education, guidelines, and systems change
    rather than patient-focused interventions.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.118297'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
